Business
Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®System in U.S. Emergency Departments
Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics – Open demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain in patients in U.S. emergency departments.
About this update from Acarix Ab
[{"type":"text","content":"Peer-reviewed research finds CADScor® strategy may reduce costs by up to $15.3M per 10,000 patients while safely ruling out heart disease ","length":137,"tagName":"p","attribs":{}},{"type":"text","content":"OKLAHOMA CITY, June 26, 2025 /PRNewswire/ -- Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics – Open demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain in patients in U.S. emergency departments.","length":347,"tagName":"p"},{"type":"image","alt":"Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. (PRNewsfoto/Acarix)","displaySize":"","headline":null,"caption":"Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. (PRNewsfoto/Acarix)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":135,"url":"https://media.zenfs.com/en/prnewswire.com/bfd421eaffb69f4ad40d72c4dd0bd23e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JyBy8gCB0Tz4OAv7lX.5aw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/bfd421eaffb69f4ad40d72c4dd0bd23e","width":400,"height":135}},"href":"https://mma.prnewswire.com/media/2719454/Acarix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The independent study, conducted by researchers at the Baim Institute for Clinical Research and leading academic hospitals in Boston, used a robust economic model to evaluate a "CADScor-First" strategy compared to standard non-invasive cardiac imaging methods. Findings revealed that integrating the CADScor® System as the initial diagnostic tool could save hospitals between $7.3 million and $15.3 million per 10,000 patients. Importantly, this cost reduction was achieved without significantly increasing patient risk or compromising diagnostic safety.","length":564,"tagName":"p"},{"type":"text","content":""This study reinforces what we at Acarix have long known — that the CADScor® System has the potential to revolutionize the early assessment of chest pain. By delivering fast, reliable results to safely rule out significant coronary artery disea...